Dillon & Associates Inc. Has $3.30 Million Stake in Eli Lilly and Company $LLY

Dillon & Associates Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 67.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,228 shares of the company’s stock after purchasing an additional 1,706 shares during the quarter. Dillon & Associates Inc.’s holdings in Eli Lilly and Company were worth $3,298,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. Lazard Freres Gestion S.A.S. boosted its holdings in Eli Lilly and Company by 114.3% in the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after purchasing an additional 41,222 shares during the period. Precedent Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 15.3% in the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after purchasing an additional 39 shares during the period. Capital Advisors Inc. OK boosted its holdings in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after purchasing an additional 429 shares during the period. Family CFO Inc bought a new stake in Eli Lilly and Company in the 2nd quarter valued at about $54,000. Finally, Duquesne Family Office LLC raised its position in shares of Eli Lilly and Company by 52.5% in the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Trading Up 3.9%

NYSE:LLY opened at $896.15 on Tuesday. The firm’s fifty day moving average is $784.74 and its 200-day moving average is $772.35. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm has a market cap of $848.17 billion, a P/E ratio of 58.57, a P/E/G ratio of 1.21 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm posted $1.18 EPS. The company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CEO David A. Ricks bought 1,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 4,514 shares of company stock valued at $2,894,841 over the last 90 days. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on LLY shares. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Cantor Fitzgerald upped their price objective on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Daiwa America cut shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $940.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.